Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
212.71B
Market cap212.71B
Price-Earnings ratio
11.04
Price-Earnings ratio11.04
Dividend yield
2.61%
Dividend yield2.61%
Average volume
10.28M
Average volume10.28M
High today
$50.68
High today$50.68
Low today
$45.59
Low today$45.59
Open price
$47.40
Open price$47.40
Volume
26.80M
Volume26.80M
52 Week high
$64.16
52 Week high$64.16
52 Week low
$35.12
52 Week low$35.12

NVO News

Simply Wall St 2h
Novo Nordisk Ziltivekimab Trial Fails In Late Stage Cardiovascular Study

Novo Nordisk (NYSE:NVO) reported that its late stage ZEUS trial of ziltivekimab in patients with atherosclerotic cardiovascular disease and chronic kidney disea...

Novo Nordisk Ziltivekimab Trial Fails In Late Stage Cardiovascular Study
Simply Wall St 14h
Why Monte Rosa Therapeutics Is Down 27.5% After Novo Nordisk’s ZEUS Trial Missed Its Goal

In late July 2026, Novo Nordisk reported that its late-stage ZEUS trial for the anti-inflammatory drug ziltivekimab did not meet its primary goal, prompting inv...

Why Monte Rosa Therapeutics Is Down 27.5% After Novo Nordisk’s ZEUS Trial Missed Its Goal
Nasdaq 24h
Novo Nordisk Shares Plunge After a Key Trial Fails. Should Investors Buy the Dip?

Key Points Shares of Danish drugmaker Novo Nordisk fell nearly 10% today. The drop came after an experimental cardiovascular drug failed a late-stage clinical...

Novo Nordisk Shares Plunge After a Key Trial Fails. Should Investors Buy the Dip?

Analyst ratings

57%

of 37 ratings
Buy
37.8%
Hold
56.8%
Sell
5.4%

More NVO News

Nasdaq 1d
Notable Two Hundred Day Moving Average Cross - NVO

In trading on Tuesday, shares of Novo-Nordisk AS (Symbol: NVO) crossed below their 200 day moving average of $106.41, changing hands as low as $106.29 per share...

Notable Two Hundred Day Moving Average Cross - NVO
TipRanks 1d
Monte Rosa, BioAge sink following Novo Nordisk’s ZEUS setback

Monte Rosa Therapeutics (GLUE) is trading lower after Novo Nordisk’s (NVO) ZEUS trial failed to show a cardiovascular benefit for IL 6 inhibition, a readout tha...

Nasdaq 1d
Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed. 1 Number Explains Why They're Not Even Close Anymore.

Key Points Both companies are giants in diabetes and obesity treatments. Lately, Eli Lilly has moved ahead in the obesity segment. Things could change, howev...

Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed. 1 Number Explains Why They're Not Even Close Anymore.
24/7 Wall St. 1d
Novo Nordisk vs Eli Lilly: The Better Buy Before Earnings

Act now: the analyst who called NVIDIA in 2010 just named his top 10 AI stocks — and Eli Lilly didn't make the cut. Grab the names FREE today . Novo pre-announ...

Novo Nordisk vs Eli Lilly: The Better Buy Before Earnings
Benzinga 1d
Why Is BioAge Labs Stock Sinking Friday?

William Blair analyst Andy Hsieh said the results from Novo Nordisk’s ZEUS trial cast doubt on the link between large reductions in high-sensitivity C-reactive...

Why Is BioAge Labs Stock Sinking Friday?
MarketWatch 1d
Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes

Shares of Novo Nordisk tumbled on Friday after the healthcare giant said that a drug it was developing to treat heart disease, kidney disease and inflammation f...

Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes
Benzinga 1d
Novo Nordisk Says Anti-Inflammatory Drug Trial Fails to Cut Cardiovascular Risk in High Risk Patients

Novo Nordisk A/S (NYSE:NVO) stock plunged on Friday after the company announced disappointing headline results from its ZEUS Phase 3 cardiovascular outcomes tri...

Novo Nordisk Says Anti-Inflammatory Drug Trial Fails to Cut Cardiovascular Risk in High Risk Patients

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.